Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer?

2009 ◽  
Vol 75 (3) ◽  
pp. S446
Author(s):  
D.V. Eastham ◽  
C.H. Chapman ◽  
A.K. Rao ◽  
B. Narasimhan ◽  
A. Quon ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Rate ◽  
Tumor Growth ◽  
Tumor Growth Rate ◽  
Pre Treatment

scholarly journals Performance of Low-dose CT Screening for Detecting Lung Cancer at the Early Stage and the Estimated Tumor Growth Rate According to the Smoking Status/Age

Haigan ◽  
2014 ◽  
Vol 54 (7) ◽  
pp. 937-946
Author(s):  
Shusuke Sone ◽  
Ryoichi Kondo ◽  
Keiko Ishii ◽  
Takayuki Honda ◽  
Kazuo Yoshida ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Rate ◽  
Tumor Growth ◽  
Low Dose ◽  
Early Stage ◽  
Smoking Status ◽  
Tumor Growth Rate ◽  
Ct Screening ◽  
Low Dose Ct

Predictive value of tumor growth rate during previous treatment for tumor response to regorafenib (REGO) and trifluridine/tipiracil (TFTD) in metastatic colorectal cancer (mCRC).

2018 ◽  
Vol 36 (4_suppl) ◽  
pp. 766-766
Author(s):  
Takeshi Kawakami ◽  
Toshiki Masuishi ◽  
Yasuyuki Kawamoto ◽  
Katsuhiro Omae ◽  
Tetsuhito Muranaka ◽  
...  
Keyword(s):  
Growth Rate ◽  
Tumor Growth ◽  
Treatment Period ◽  
Tumor Response ◽  
Previous Treatment ◽  
Target Lesion ◽  
Tumor Growth Rate ◽  
Long Duration ◽  
Pre Treatment ◽  
Slow Growing

766 Background: Although REGO and TFTD have been recognized as standard salvage treatments for patients (pts) with refractory mCRC, it is still unclear which drug should be used first. Tumor growth rate (TGR) during the pre-treatment period is associated with survival in lung and laryngeal cancer treated with chemoradiotherapy. However, little is known about the association between TGR during the pre-treatment period and tumor response to REGO and TFTD. Methods: We retrospectively analyzed the data of consecutive mCRC pts who were treated with REGO or TFTD at three institutions. We classified pts into slow-growing (SG) or rapid-growing (RG) groups according to TGR, and appearance of new lesions (NL+) or their absence (NL–) during the pre-treatment period. TGR was calculated as follows: TGR = (D1 − D0)/100D0 (CT1 − CT0), where CT1 is the date of computed tomography (CT) at progressive disease, CT0 is the date of CT before CT1, and Dn is the sum of target lesion diameters at CTn (according to RECIST version 1.1). SG was defined as NL– with a low TGR ( < 0.33), and RG was defined as NL− with a high TGR (≥0.33) or NL+, irrespective of TGR. Results: A total of 244 pts (RG/SG: 133/111, REGO/TFTD: 132/112) were eligible. The proportion of RG pts with a long duration from first-line chemotherapy and SG pts with elevated ALP was higher in the REGO group, while the proportion of SG pts with poor PS was higher in the TFTD group. The disease control rate (DCR) was similar in both groups (REGO 29% vs TFTD 23%, p = 0.556) among RG pts, while the DCR of TFTD was significantly better than REGO in SG pts In a multivariate analysis of predictive factors for DCR, drug selection was an independent factor for DCR in SG pts (odds ratio 3.51; 95% CI 1.33-9.27; p = 0.011). In RG group, DCRs of NL+ pts were worse than that of NL- pts (16% vs 36% in REGO group, p = 0.109; 9% vs. 31% in TFTD group, 0.108). Conclusions: TGR during the pre-treatment period would be helpful in selecting between REGO and TFTD, especially for pts with slow-growing tumors. Pts with appearance of new lesions may not benefit from either REGO or TFTD as salvage treatment.

Effect of tumor growth rate (TGR) on response patterns of checkpoint inhibitors in non-small cell lung cancer (NSCLC).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 9034-9034 ◽  
Author(s):  
Jihene Lahmar ◽  
Francesco Facchinetti ◽  
Serge Koscielny ◽  
Charles Ferte ◽  
Laura Mezquita ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Rate ◽  
Tumor Growth ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitors ◽  
Small Cell ◽  
Tumor Growth Rate ◽  
Response Patterns ◽  
Small Cell Lung

scholarly journals Pre-Treatment Tumor Growth Rate Predicts Clinical Outcomes of Patients With Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD-1/PD-L1 Therapy

2021 ◽  
Vol 10 ◽  
Author(s):  
Li-na He ◽  
Xuanye Zhang ◽  
Haifeng Li ◽  
Tao Chen ◽  
Chen Chen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Rate ◽  
Small Cell Lung Cancer ◽  
Clinical Benefit ◽  
Cox Regression ◽  
Small Cell ◽  
Tumor Growth Rate ◽  
Small Cell Lung ◽  
Pre Treatment

Tumor growth rate (TGR; percent size change per month [%/m]) is postulated as an early radio-graphic predictor of response to anti-cancer treatment to overcome limitations of RECIST. We aimed to evaluate the predictive value of pre-treatment TGR (TGR0) for outcomes of advanced non-small cell lung cancer (aNSCLC) patients treated with anti-PD-1/PD-L1 monotherapy. We retrospectively screened all aNSCLC patients who received PD-1 axis inhibitors in Sun Yat-Sen University Cancer Center between August 2016 and June 2018. TGR0 was calculated as the percentage change in tumor size per month (%/m) derived from two computed tomography (CT) scans during a “wash-out” period before the initiation of PD-1 axis inhibition. Final follow-up date was August 28, 2019. The X-tile program was used to identify the cut-off value of TGR0 based on maximum progression-free survival (PFS) stratification. Patients were divided into two groups per the selected TGR0 cut-off. The primary outcome was the difference of PFS between the two groups. The Kaplan-Meier methods and Cox regression models were performed for survival analysis. A total of 80 eligible patients were included (54 [67.5%] male; median [range] age, 55 [30-74] years). Median (range) TGR0 was 21.1 (-33.7-246.0)%/m. The optimal cut-off value of TGR0 was 25.3%/m. Patients with high TGR0 had shorter median PFS (1.8 months; 95% CI, 1.6 - 2.1 months) than those with low TGR0 (2.7 months; 95% CI, 0.5 - 4.9 months) (P = 0.005). Multivariate Cox regression analysis revealed that higher TGR0 independently predicted inferior PFS (hazard ratio [HR] 1.97; 95% CI, 1.08-3.60; P = 0.026). Higher TGR0 was also significantly associated with less durable clinical benefit rate (34.8% vs. 8.8%, P = 0.007). High pre-treatment TGR was a reliable predictor of inferior PFS and clinical benefit in aNSCLC patients undergoing anti-PD-1/PD-L1 monotherapy. The findings highlight the role of TGR0 as an early biomarker to predict benefit from immunotherapy and could allow tailoring patient’s follow-up.

scholarly journals Tumor Growth Rate After Nadir Is Associated With Survival in Patients With EGFR-Mutant Non–Small-Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

2021 ◽  
pp. 1603-1610
Author(s):  
Mizuki Nishino ◽  
Junwei Lu ◽  
Takuya Hino ◽  
Natalie I. Vokes ◽  
Pasi A. Jänne ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Rate ◽  
Tumor Growth ◽  
Tumor Volume ◽  
Advanced Nsclc ◽  
Regression Coefficient ◽  
Small Cell ◽  
Tumor Growth Rate ◽  
Small Cell Lung ◽  
Egfr Mutant

PURPOSE To investigate the association between tumor volume growth rate after the nadir and survival in patients with EGFR-mutant advanced non–small-cell lung cancer (NSCLC) treated with erlotinib. MATERIALS AND METHODS Seventy-one patients with EGFR-mutant advanced NSCLC treated with erlotinib were studied for computed tomography tumor volume kinetics during therapy. The tumor growth rate after nadir was obtained using a previously published analytic module for longitudinal volume tracking to study its relationship with overall survival (OS). RESULTS The median tumor volume for the cohort was 19,842 mm3 at baseline and 4,083 mm3 at nadir. The median time to nadir was 6.2 months. The tumor growth rate after nadir for logeV (the natural logarithm of tumor volume measured in mm3) was 0.11/mo on average for the cohort (SE: 0.014), which was very similar to the previously validated reference value of 0.12/mo to define slow and fast tumor growth. The OS of 48 patients with slow tumor growth (≤ 0.12/mo) was significantly longer compared with 23 patients with fast tumor growth (> 0.12/mo; median OS: 37.8 v 25.0 months; P = .0012). In Cox models, tumor growth rate was also associated with survival (regression coefficient: 3.9903; P = .0024; faster rate leads to increased hazards), after adjusting for time to nadir (regression coefficient: –0.0863; P = .0008; longer time to nadir leads to decreased hazards) and smoking history. CONCLUSION In patients with EGFR-mutant advanced NSCLC treated with erlotinib, slower tumor growth rates after nadir were associated with longer OS, providing a rationale for using tumor growth rates to guide precision therapy for lung cancer.

scholarly journals Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib

2020 ◽  
Vol 7 ◽  
pp. 100210
Author(s):  
Mizuki Nishino ◽  
Tomoyuki Hida ◽  
Sasha Kravets ◽  
Suzanne E. Dahlberg ◽  
Christine A. Lydon ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Growth Rate ◽  
Tumor Growth ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Volume ◽  
Small Cell ◽  
Tumor Growth Rate ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document